EN DE
Watch Taysha Gene Therapies Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Taysha Gene Therapies Inc (TSHA) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Taysha Gene Therapies Inc stock $2.30, price $4.06, that is 43.3% below the price, quality 32 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US8776191061

TG Taysha Gene Therapies Inc logo Thin data Nov 16, 2026

Taysha Gene Therapies Inc

TSHA · US

Far too expensive (fair value 43% below the price), weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Price moving sideways (no uptrend) 
Mixed Growth (revenue 3y +57.5 %/yr in USD) 
Insiders sold $1.2M (6M) 
Fair value $2.30 · Strongly overvalued 
Quality 32/100 
Negative free cash flow 
Trails peers (1/7) 
Narrow moat 9/100
Thin data 
Estimate
Watch Taysha Gene Therapies Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$21.57 $0.5900 Fair Value $2.30 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range $0.5900 – $21.57 · fair‑value band $1.72 – $2.87 · the $4.06 price screens above the $2.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Taysha Gene Therapies in your weekly email

Every Wednesday you see whether Taysha Gene Therapies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

Show moreShow less

The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.

The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Stock analysis

Taysha Gene Therapies Inc (TSHA) currently trades at $4.06, while our estimate is $2.30, 43% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.72 (bear) to $2.87 (bull), the price of $4.06 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Taysha Gene Therapies Inc reported revenue of $9.8M in FY2025 versus $0 in FY2021. Reported net income was −$109M in FY2025.

Key figures

Market cap $1.5B Small · EPS (TTM) $−0.4200 · Return on equity −54.2% · Return on assets (EBIT) −62.4% (5-year average) · Operating margin −2,998% · Revenue (TTM) $5.5M · Revenue growth (YoY) +171% · Free cash flow −$93.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 42% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −43%, TSHA screens richer than that median.

Fair Value

Bear $1.72 Fair Value $2.30 Bull $2.87
Price $4.06 · Downside -43.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 53
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 23
Does it invest with discipline instead of growing at any price?
Low Volatility 19
How calm the share price moves, does not count
Price momentum 11
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 25
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $1.2M and none bought.

  • SaleSukumar NagendranPresident and Head of R&D, Director5× since Nov 28, 2025: 1,086,222 shares, avg. $4.90$5.3MJul 10, 2026
  • SaleKamran AlamCHIEF FINANCIAL OFFICER2× since Jan 23, 2026: 104,472 shares, avg. $4.71$492,522Feb 4, 2026
  • SaleSean P. NolanChief Executive Officer, Director178,101 shares at $4.72$840,196Jan 26, 2026

Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+17.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+57.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,037.1% (2022) → −1,130.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

TSHA screens overvalued: fair value 43% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Taysha Gene Therapies Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Below median
Fair Value upside −43.3% · Bottom 25%
Profitability
Return on assets −31.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 171.3% · Top 25%
Balance sheet
Debt / equity 0.20× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.07× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)90 · sector 96
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs TSHA
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs TSHA
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs TSHA
argenx SE ARGX $950.95 $908.40 −4% vs TSHA
CSL Limited CSL A$199.55 A$186.49 −7% vs TSHA
Moderna, Inc MRNA $215.27 $135.64 −37% vs TSHA
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs TSHA
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs TSHA
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs TSHA
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs TSHA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Taysha Gene Therapies Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Taysha Gene Therapies Inc Fair Value". https://www.fairvalue-calculator.com/stock/TSHA

Frequently asked questions

Is Taysha Gene Therapies Inc (TSHA) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is $2.30 versus a price of $4.06, about 43% lower (overvalued).
What is the fair value of TSHA?
Our estimate for Taysha Gene Therapies Inc is $2.30 (as of Nov 16, 2026), built from audited fundamentals. The current price: $4.06.
What is the quality score of TSHA?
Taysha Gene Therapies Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Taysha Gene Therapies Inc (TSHA)?
Our calculated price target is the estimate of $2.30 (as of Nov 16, 2026). Cautious scenario $1.72, optimistic scenario $2.87. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Taysha Gene Therapies Inc stock forecast for 2026?
Our estimate puts fair value at $2.30, about 43% lower versus a price of $4.06 (overvalued). Cautious scenario $1.72, optimistic scenario $2.87. The calculation is refreshed regularly with new filings.
What is the revenue of Taysha Gene Therapies Inc (TSHA)?
Taysha Gene Therapies Inc reported trailing-twelve-month revenue of about $5.5M (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Taysha Gene Therapies Inc (TSHA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Taysha Gene Therapies Inc it is $2.30 per share (as of Nov 16, 2026), against a price of $4.06.
Is Taysha Gene Therapies Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, TSHA trades above its calculated fair value: price $4.06, fair value $2.30, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TSHA?
No. The price is what the market pays today ($4.06); the fair value is what the company's own numbers justify ($2.30). For Taysha Gene Therapies Inc the two are $1.76 per share apart. That gap is exactly why we show both numbers side by side.
How much is Taysha Gene Therapies Inc worth?
The market values Taysha Gene Therapies Inc at about $1.5B (market capitalisation, as of Nov 16, 2026). Per share that is $4.06; our models calculate a fair value of $2.30 per share.
What do the bullish and bearish scenarios say about TSHA?
Our models span a range for Taysha Gene Therapies Inc: cautious scenario $1.72, base $2.30, optimistic $2.87 per share (as of Nov 16, 2026, price $4.06). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Taysha Gene Therapies Inc (TSHA)?
Balance-sheet figures for Taysha Gene Therapies Inc (as of Nov 16, 2026): return on equity −54.2%, debt of 0.20 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is TSHA from its 52-week high?
Taysha Gene Therapies Inc trades at $4.06, about 42% below its 52-week high of $6.98 and 16% above the low of $3.51 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $2.30 is for.
Which stocks are comparable to Taysha Gene Therapies Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Taysha Gene Therapies Inc stock attractive at the current price?
The data as of Nov 16, 2026: price $4.06, calculated fair value $2.30 (−43%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Taysha Gene Therapies Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Taysha Gene Therapies Inc (TSHA)?
The closing price on Nov 16, 2026 was $4.06. Our estimate is $2.30, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Taysha Gene Therapies Inc right now?
The price sits above even our optimistic bull case ($2.87). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Taysha Gene Therapies Inc

How large is the market capitalisation of Taysha Gene Therapies Inc (TSHA)?
The market capitalisation of Taysha Gene Therapies Inc is $1.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Taysha Gene Therapies Inc (TSHA)?
Earnings per share at Taysha Gene Therapies Inc are $−0.4200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Taysha Gene Therapies Inc (TSHA)?
The return on equity (ROE) of Taysha Gene Therapies Inc is −54.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Taysha Gene Therapies Inc (TSHA)?
On an EBIT basis the return on assets of Taysha Gene Therapies Inc is −62.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Taysha Gene Therapies Inc (TSHA)?
The operating margin of Taysha Gene Therapies Inc is −2,998% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Taysha Gene Therapies Inc (TSHA)?
Revenue at Taysha Gene Therapies Inc is growing 171% versus a year earlier (3y avg +57.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Taysha Gene Therapies Inc (TSHA) generate?
The free cash flow of Taysha Gene Therapies Inc is −$93.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Taysha Gene Therapies Inc (TSHA) hold?
Taysha Gene Therapies Inc holds more cash than debt, $302M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Taysha Gene Therapies Inc in the live analysis

One click puts Taysha Gene Therapies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.